MALDI BIOTYPER CA (MBT-CA) SYSTEM

The Bruker Daltonics MBT-CA System is an in vitro diagnostic tool employing MALDI-TOF mass spectrometry to identify Gram-negative bacteria cultured from human specimens by analyzing their unique ribosomal protein profiles against a reference spectral library. Extensive performance studies demonstrate its high accuracy, precision, and specificity, with robust identification achieved through either direct sample transfer or an optional extraction step, ensuring reliable diagnostic support.

The Bruker Daltonics MBT-CA System is a qualitative in vitro diagnostic mass spectrometer designed for identifying Gram-negative bacterial colonies cultured from human specimens. It utilizes Matrix-Assisted Laser Desorption/Ionization - Time of Flight (MALDI-TOF) mass spectrometry to generate unique protein profiles, primarily of ribosomal proteins, from microorganisms. The process involves transferring an isolated colony directly to a target plate (Direct Transfer method) or, if initial results are inconclusive, performing an ethanol/formic acid extraction. The sample is overlaid with an α-Cyano-4-hydroxycinnamic acid (HCCA) matrix, which extracts proteins and facilitates ionization when irradiated by a laser. The system measures the time-of-flight of these ions to determine their mass-to-charge ratios, creating a characteristic mass spectrum. This spectrum is then compared against a reference library, and a biostatistical algorithm generates a log(score) indicating the confidence of identification, with scores ≥2.00 considered high confidence. Extensive performance data supports the MBT-CA System's reliability. Method comparison studies involving 2263 isolates showed high accuracy, with 96.07% identified with high confidence and 98.19% correctly identified to the species or group level when combining high and low confidence results; fresh isolates showed 98.0% high discrimination. The system demonstrated excellent precision and reproducibility across different operators, instruments, sites, and reagent lots, with a 100% correct identification rate for blinded test organisms in reproducibility studies. Specificity studies confirmed that organisms not in its database yield 'No Identification' results, preventing false positives. The system also showed robustness against mixed cultures (though single colonies are recommended), stability with various approved culture media, and long-term stability of samples on target plates and reagents like the Bacterial Test Standard (BTS) and HCCA matrix. An extraction procedure was required for only 6.9% of samples in the method comparison study.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the system's performance, particularly the log(score) distribution and need for extraction, vary across the spectrum of claimed Gram-negative species, especially for those with known high phenotypic or proteomic variability?; What is the quantitative impact of different approved culture media (e.g., MacConkey vs. Chocolate agar) on the generated mass spectra quality and resulting log(scores), and does this correlate with the need for the extraction protocol?; Considering the 6.9% extraction rate, what are the most common organism- or sample-related factors leading to initial low-confidence scores (<2.0) with the Direct Transfer method, and how does this compare to typical rates with similar MALDI-TOF systems?; How frequently is the MBT-CA reference database updated to include new Gram-negative strains or species, and what is the validation process for these updates to ensure continued specificity and accuracy?; What is the typical turnaround time difference, including hands-on and instrument time, between a successful Direct Transfer identification and one requiring the full Extraction procedure, and how does this affect laboratory throughput for challenging isolates?